Quest Diagnostics (NYSE: DGX) SVP sells 526 shares in plan

Rhea-AI Filing Summary

Quest Diagnostics senior vice president and general counsel Michael E. Prevoznik reported recent stock transactions. On March 3, he executed an open-market sale of 526 shares of common stock at $207.73 per share under a Rule 10b5-1 sales plan, leaving 37,557 shares held directly afterward. On March 2, 288 shares were disposed of at $204.86 per share to cover tax obligations from the vesting of restricted share units. He also has 5,737 shares held indirectly through company 401(k) and deferred compensation plans.

Insider Trade Summary

Net Seller: 526 shares ($109,266)

Net Sell 3 txns

Insider PREVOZNIK MICHAEL E

Role SVP & General Counsel

Sold 526 shs ($109K)

Type	Security	Shares	Price	Value
Sale	Common Stock	526	$207.73	$109K
Tax Withholding	Common Stock	288	$204.86	$59K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 37,557 shares (Direct); Common Stock — 5,737 shares (Indirect, 401(k)/SDCP)

Footnotes (1)

1. Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PREVOZNIK MICHAEL E

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		F		288(1)	D	$204.86	38,083	D
Common Stock	03/03/2026		S(2)		526	D	$207.73	37,557	D
Common Stock								5,737(3)	I	401(k)/SDCP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units.

2. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

3. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Michael E. Prevoznik	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did Quest Diagnostics (DGX) disclose for Michael E. Prevoznik?

Quest Diagnostics reported that SVP and general counsel Michael E. Prevoznik sold 526 shares of common stock in an open-market transaction and disposed of 288 shares to cover taxes from restricted share unit vesting, according to the Form 4 filing.

At what prices did the Quest Diagnostics (DGX) insider transactions occur?

The open-market sale of Quest Diagnostics common stock was at $207.73 per share for 526 shares. A separate 288-share tax-withholding disposition tied to restricted share unit vesting occurred at $204.86 per share, based on the reported transaction details.

How many Quest Diagnostics (DGX) shares does Michael E. Prevoznik hold after these transactions?

After the reported transactions, Michael E. Prevoznik holds 37,557 Quest Diagnostics shares directly. He also has 5,737 shares held indirectly through the company’s 401(k) and supplemental deferred compensation plans, as reflected in the Form 4 data.

Was the Quest Diagnostics (DGX) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 notes that the 526-share open-market sale of Quest Diagnostics common stock by Michael E. Prevoznik was executed pursuant to a pre-established Rule 10b5-1 sales plan adopted by the reporting person.

Why did the Quest Diagnostics (DGX) insider dispose of 288 shares on March 2, 2026?

The 288-share disposition on March 2 was used to satisfy tax obligations arising from the vesting of a prior restricted share unit grant. This transaction is described as payment of tax liability by delivering securities.

How are Michael E. Prevoznik’s indirect Quest Diagnostics (DGX) holdings structured?

His indirect Quest Diagnostics holdings are in the company’s tax-qualified profit sharing 401(k) and supplemental deferred compensation plans. Shares are acquired periodically by the plan trustee, with amounts based on the stock fund balance and current market price.